Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2004 2
2005 2
2008 1
2009 1
2011 2
2012 2
2013 3
2014 5
2015 3
2016 1
2017 3
2018 8
2019 7
2020 10
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

47 results
Results by year
Filters applied: . Clear all
Page 1
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma.
Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY. Mellinghoff IK, et al. Among authors: cote gm. J Clin Oncol. 2020 Oct 10;38(29):3398-3406. doi: 10.1200/JCO.19.03327. Epub 2020 Jun 12. J Clin Oncol. 2020. PMID: 32530764 Clinical Trial.
Contemporary Sarcoma Diagnosis, Genetics, and Genomics.
Schaefer IM, Cote GM, Hornick JL. Schaefer IM, et al. Among authors: cote gm. J Clin Oncol. 2018 Jan 10;36(2):101-110. doi: 10.1200/JCO.2017.74.9374. Epub 2017 Dec 8. J Clin Oncol. 2018. PMID: 29220288 Review.
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S. Gounder M, et al. Among authors: cote gm. Lancet Oncol. 2020 Nov;21(11):1423-1432. doi: 10.1016/S1470-2045(20)30451-4. Epub 2020 Oct 6. Lancet Oncol. 2020. PMID: 33035459 Clinical Trial.
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Tap WD, Villalobos VM, Cote GM, Burris H, Janku F, Mir O, Beeram M, Wagner AJ, Jiang L, Wu B, Choe S, Yen K, Gliser C, Fan B, Agresta S, Pandya SS, Trent JC. Tap WD, et al. Among authors: cote gm. J Clin Oncol. 2020 May 20;38(15):1693-1701. doi: 10.1200/JCO.19.02492. Epub 2020 Mar 24. J Clin Oncol. 2020. PMID: 32208957 Free PMC article. Clinical Trial.
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcoma.
Lietz CE, Garbutt C, Barry WT, Deshpande V, Chen YL, Lozano-Calderon SA, Wang Y, Lawney B, Ebb D, Cote GM, Duan Z, Hornicek FJ, Choy E, Petur Nielsen G, Haibe-Kains B, Quackenbush J, Spentzos D. Lietz CE, et al. Among authors: cote gm. Sci Rep. 2020 Mar 10;10(1):4409. doi: 10.1038/s41598-020-61236-3. Sci Rep. 2020. PMID: 32157112 Free PMC article.
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Berezhnoy A, Sumrow BJ, Stahl K, Shah K, Liu D, Li J, Hao SS, De Costa A, Kaul S, Bendell J, Cote GM, Luke JJ, Sanborn RE, Sharma MR, Chen F, Li H, Diedrich G, Bonvini E, Moore PA. Berezhnoy A, et al. Among authors: cote gm. Cell Rep Med. 2020 Dec 22;1(9):100163. doi: 10.1016/j.xcrm.2020.100163. eCollection 2020 Dec 22. Cell Rep Med. 2020. PMID: 33377134 Free PMC article.
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma.
Keskin T, Bakaric A, Waszyk P, Boulay G, Torsello M, Cornaz-Buros S, Chevalier N, Geiser T, Martin P, Volorio A, Iyer S, Kulkarni A, Letovanec I, Cherix S, Cote GM, Choy E, Digklia A, Montemurro M, Chebib I, Nielsen PG, Carcaboso AM, Mora J, Renella R, Suvà ML, Fusco C, Provero P, Rivera MN, Riggi N, Stamenkovic I. Keskin T, et al. Among authors: cote gm. Cell Rep. 2020 Apr 14;31(2):107539. doi: 10.1016/j.celrep.2020.107539. Cell Rep. 2020. PMID: 32294441 Free article. No abstract available.
Update in treatment and targets in Ewing sarcoma.
Cote GM, Choy E. Cote GM, et al. Hematol Oncol Clin North Am. 2013 Oct;27(5):1007-19. doi: 10.1016/j.hoc.2013.07.001. Epub 2013 Aug 3. Hematol Oncol Clin North Am. 2013. PMID: 24093173 Review.
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability.
Keskin T, Bakaric A, Waszyk P, Boulay G, Torsello M, Cornaz-Buros S, Chevalier N, Geiser T, Martin P, Volorio A, Iyer S, Kulkarni A, Letovanec I, Cherix S, Cote GM, Choy E, Digklia A, Montemurro M, Chebib I, Nielsen PG, Carcaboso AM, Mora J, Renella R, Suvà ML, Fusco C, Provero P, Rivera MN, Riggi N, Stamenkovic I. Keskin T, et al. Among authors: cote gm. Cell Rep. 2020 Mar 31;30(13):4567-4583.e5. doi: 10.1016/j.celrep.2019.12.053. Cell Rep. 2020. PMID: 32234488 Free article.
47 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page